6:03 AM ET
10-Q
Financial Results
Silence Therapeutics Q3 2026 Results: Net Loss of $12.4M, Loss Narrows
Silence Therapeutics reported a net loss of $39.7 million for the nine months ended September 30, 2026, a significant improvement from the $76.8 million loss in the prior year period. The company strengthened its balance sheet through a major share issuance in the third quarter, bringing cash and cash equivalents to $247.7 million, which management believes will fund operations until at least 2028.
- Key figure
- Net loss $12.4M